23 results about "Yohimbine" patented technology

A pharmaceutical composition and method for treating opioid overdose, opioid dependency, and xylazine exposure is disclosed, utilizing an aqueous solution of sodium chloride. This solution contains active ingredients such as naloxone and yohimbine in specific concentrations, with naloxone targeting opioid overdose and yohimbine aimed at counteracting xylazine effects. In various embodiments, additional components like tolazoline and different buffers can be included. The disclosure introduces a unique delivery system that features a capsule with a vibrating mesh atomizer for efficient administration. Specifically, for yohimbine, a dual-reservoir capsule design facilitates controlled mixing with diluents or buffers. The administration of this pharmaceutical composition can be achieved through multiple methods, including intramuscular, intravenous, and atomized routes. The atomizing device incorporates a removable cap and a resilient air bladder, ensuring effective drug delivery. This system offers precision and adaptability in treating conditions related to opioid overdose, dependency, and xylazine exposure.

A liquid preparation, a method for preparing the liquid preparation, an aerosol generation system, a cartridge for the aerosol generation system, and an aerosol generation apparatus are provided. The liquid preparation includes a yohimbine extract, a chaotropic agent and a solvent, where the solubility of the yohimbine extract in the chaotropic agent is greater than the solubility of the yohimbine extract in the solvent; and the yohimbine extract can form a stable and transparent solution with the solvent after being dissolved in the chaotropic agent. The yohimbine extract is dissolved in the chaotropic agent and then mixed with the solvent in the liquid preparation, the use amount of the yohimbine extract in the aerosol generation system is increased by dissolving the yohimbine extract in the chaotropic agent, then mixing with the solvent of the liquid preparation, thereby promoting the use of the yohimbine extract in the aerosol generation system.

The invention relates to the technical field of medicines, in particular to application of yohimbine hydrochloride and a related product. The invention provides application of yohimbine hydrochloride or pharmaceutically acceptable salt thereof in preparation of products for preventing or treating hypertension, and further provides application of yohimbine hydrochloride or pharmaceutically acceptable salt thereof in preparation of products for preventing or treating vasculopathy caused by hypertension and / or heart disease caused by hypertension. It is found for the first time that yohimbine hydrochloride can be applied to preparation of the medicine for preventing or treating hypertension or heart and vasculopathy caused by hypertension, the treatment effect is good, safety is achieved, and a new treatment approach is provided for treating hypertension or hypertension-related diseases.

A yohimbine derivative, and a preparation method therefor and a pharmaceutical composition and use thereof. The biological structure of the yohimbine derivative is as shown by formula (I), wherein the definitions of the substituents in the formula are as stated in the description and claims. The yohimbine derivative is used as an α2A-AR antagonist, and can be used for treating diseases such as diabetes.

The invention relates to the technical field of food safety detection, discloses a method for rapidly determining 17 novel veterinary drug compounds in animal-derived food by combining solid-phase extraction with HPLC-MS / MS (High Performance Liquid Chromatography-Mass Spectrometry / Mass Spectrometry), and relates to an HPLC-MS / MS method for determining 17 novel veterinary drug residues such as yohimbine, medetomidate and tripinramine in chicken, beef, fish and shrimp. Trade barriers and economic losses caused by drug residues can be avoided; comprising the following steps: 1) preparing standard stock solutions with different concentrations by using standard substances of 17 novel veterinary drug compounds, and mixing standard working stock solutions; a series of working standard solutions are prepared by using the standard stock solution and are used for HPLC-MS / MS detection; 2) adding the mixed standard working stock solution into extracted and purified blank sample residues to prepare a series of matrix matching mixed standard solutions with different concentrations, filtering the mixed standard solutions, and loading the mixed standard solutions on a machine for detection, and 3) homogenizing the samples of cattle, chicken, fish and prawns, carrying out subsequent treatment, and carrying out HPLC-MS / MS online analysis on the obtained samples.

The present invention relates to a composition for inhibiting angiogenesis containing yohimbine, and more specifically, to a pharmaceutical preparation and a functional food containing a composition capable of exhibiting preventive, improving, and therapeutic effects on angiogenesis-related diseases such as hemangioma, vascular adhesion, neovascular glaucoma, diabetic retinopathy, macular degeneration, corneal disease caused by neovascularization, or telangiectasia by containing yohimbine capable of inhibiting PDGF-induced vascular smooth muscle cell proliferation and migration through the factor FOXO3a.

Disclosed in the present invention are a yohimbine derivative, and a preparation method therefor and a pharmaceutical composition and use thereof. The structure of the yohimbine derivative is as shown in formula I, and the definition of each substituent in the formula is as described in the description and the claims. The yohimbine derivative of the present invention is used as an α2A-AR antagonist and can be used for treating diseases such as diabetes and diabetic nephropathy.

The invention discloses a yohimbine derivative as well as a preparation method, a pharmaceutical composition and application thereof, the structure of the yohimbine derivative is as shown in formula I. In the formula, the definition of each substituent group is as described in the specification and claims. The yohimbine derivative disclosed by the invention is used as an alpha2A-AR antagonist and can be used for treating diseases such as diabetes mellitus and diabetic nephropathy.

The invention provides a method of promoting weight management in a mammal comprising administering to the mammal a composition comprising at least one weight loss agent and at least one mitochondrial enhancer. The weight loss agent can be selected from the group consisting of psyllium, guar gum, capsaicin, chitosan, caffeine, gamboge, mume, capsaicin, yohimbine, butterfly pea, glucomannan, African mango, guarana, pyruvate, carnitine, beta-glucan, fucoxanthin, raspberry ketone, white kidney bean, kola nut, chromium, ginseng, psyllium, St. John's wort, dandelion, hydroxycitric acid, conjugated linoleic acid, green tea, black tea, coffee bean extract, forskolin, and bitter orange. The mitochondrial enhancer can be selected from the group consisting of beetroot extract, nitrate, idebenone, nicotinamide riboside, elamipretide, vitamin C, vitamin D, vitamin E, thiamine, riboflavin, magnesium, calcium, phosphate, phospholipid, creatine, pyruvate, coenzyme Q10, NADH, niacin, L-carnitine, dichloroacetate, curcumin, schisandrin, and resveratrol. Compositions for weight management are also provided.

The present application provides the use of antagonists of tyramine-ADRA2A signaling axis in the preparation of a medicament for preventing and / or treating inflammatory bowel disease. By using antagonists of tyramine-ADRA2A signaling axis, including but not limited to yohimbine, midaglizole and 2-methoxyimidazolidine, the activation of ADRA2A receptors on intestinal stem cells by tyramine can be inhibited, and the proliferation of intestinal stem cells, the repair of damaged intestines and the relief of intestinal inflammation can be restored. The present application lays a new material foundation for the treatment of inflammatory bowel disease, especially Crohn's disease.

A pharmaceutical composition in the form of droplets for oral administration is disclosed. The pharmaceutical composition is an aqueous solution comprising sodium chloride in an amount of 0.6% to 3% by weight per volume, at least one active ingredient selected from naloxone, yohimbine, albuterol, epinephrine, buprenorphine, and exosomes in an amount of 0.01% to 25% by weight per volume, and having a pH from 3 to 7.5. The composition is converted into droplets with diameters of 0.5 to 5 microns using an atomizer with a vibrating mesh membrane undergoing piezoelectric vibration at a frequency of 25 to 400 kilohertz. The process involves providing the composition in a capsule, inserting the capsule into the atomizer, and activating the atomizer to produce droplets. This system provides precise, efficient, and patient-friendly oral delivery of medications.

The invention discloses yohimbine alkaloids as well as a preparation method and application thereof. The yohimbine alkaloid is at least one of a compound 1 to a compound 8. According to the application, novel yohimbine type alkaloid compounds, namely compounds 1 to 8, are found from neriaceae Abrus dichroa plant Codonopsis lanceolata, and research finds that the yohimbine type alkaloid compounds have a remarkable inhibitory effect on protein tyrosine phosphatase, and can be used for preparing a medicine for preventing and treating the diseases caused by the protein tyrosine phosphatase. The invention provides a novel scheme and product for preparing the protein tyrosine phosphatase inhibitor or a therapeutic drug based on the protein tyrosine phosphatase inhibitor.

The structure of the yohimbine derivative is as shown in Formula I, and the definitions of each substituent in the formula are as described in the specification and claims. The yohimbine derivative can be used as an α2A-AR antagonist to treat diseases such as diabetes.

Described herein are lifesaving compositions and methods including the administration of alpha-2 (α2) adrenergic antagonists as a drug class for use in the reversal of substance overdose that can be contributed to by xylazine and xylazine congeners, alcohol, fentanyl / opioids, and benzodiazepines in humans. In some instances, the substance overdoses can appear to be opioid induced but are not responsive to administration of therapeutic agents (e.g., Naloxone administration). The antagonists can be safely and quickly produced using yohimbine, and the compositions and methods are operative to address the United States' national crisis of human overdoses caused by combining various illicit (street) drugs with xylazine.

Yohimbine derivatives, their preparation methods, and uses. This invention discloses compounds of Formula I and pharmaceutical compositions comprising compounds of Formula I. The compounds of Formula I of this invention, as adrenaline receptor α2A (ADRA2A) antagonists or partial antagonists, can treat and / or prevent inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), Crohn's disease (CD), or enteritis.

The invention discloses a synthesis method of spirooxindole, Cauhinin and yohimbine alkaloids and derivatives thereof. Belongs to the field of pharmaceutical chemicals. The invention relates to intermediate compounds for preparing indole alkaloid, a synthesis method of the intermediate compounds, and a method for synthesizing spiro-oxoindole alkaloid and derivatives of the spiro-oxoindole alkaloid by utilizing the intermediate compounds based on intramolecular dehydrogenation coupling reaction. The invention also relates to a synthesis method of the Cauhinine and yohimbine alkaloids and the derivatives thereof. The synthesis method has high functional group compatibility and broad-spectrum substrate universality, raw materials can be prepared in a large scale, reagents are low in price and easy to obtain, operation is easy, steps are short, and important popularization potential and application value are achieved.

A method for making a sulfur cathode, comprising steps oF mixing sulfur and an amount of a purine compound in a weight ratio of sulfur to purine of from less than 10:1 to greater than 2:1 to form a powder mixture; mixing the powder mixture with a solvent to form a slurry; and drying the slurry onto a current collector to form the sulfur cathode. A cathode for use in a lithium sulfur battery including sulfur; and an purine selected from the group consisting of caffeine, nicotine, morphine, codeine, quinine, atropine, ephedrine, strychnine, colchicine, theobromine, theophylline, papaverine, reserpine, coniine, harmine, ibogaine, vinblastine, vincristine, yohimbine, capsaicin, camptothecin, mitragynine, apomorphine, psilocybin, scopolamine, tetrahydrocannabinol (THC), salvinorin A, mescaline, muscarine, preferably, the purine is caffeine. Also disclosed are electrolytes and batteries.

The present invention relates to the technical field of antiviral drugs, and specifically discloses the application of yohimbine in the preparation of drugs for treating respiratory syncytial virus infection. The application of yohimbine in the preparation of drugs for treating respiratory syncytial virus infection provided by the present invention proves that yohimbine can inhibit the proliferation of respiratory syncytial virus and its infection of host cells, and can be used as a specific drug for treating diseases caused by respiratory syncytial virus infection.

A pharmaceutical composition may include clomipramine or a pharmaceutically acceptable salt form thereof and yohimbine or a pharmaceutically acceptable salt form thereof and may be used in the treatment and prevention of premature ejaculation. The composition may contain, for example, 5 to 150 mg clomipramine, and / or, for example, 5 to 150 mg yohimbine.

The use of yohimbine drug in the treatment of type 2 diabetes. The yohimbine drug achieves the effect of treating type 2 diabetes by reducing the fasting blood glucose, reducing the glucose tolerance and reducing the insulin resistance in patients with diabetes.

The invention discloses a pharmaceutical composition and application thereof in preparation of a medicine for treating major depressive disorder. The pharmaceutical composition is prepared from esketamine and yohimbine. The yohimbine in the pharmaceutical composition provided by the invention can effectively promote the anti-depression effect of the esketamine, remarkably reduce the use dosage of the esketamine when the esketamine plays the anti-depression effect and prolong the duration of the anti-depression effect, and meanwhile, a certain dosage of yohimbine can promote a smaller dosage of esketamine to play the anti-depression effect.

The present invention relates to a method for preparing yohimbine by using supercritical extraction combined with steaming technology. The method solves the technical problems of incomplete extraction of existing yohimbine, low yield, complex process, long production cycle, high cost, and unsuitability for industrial production. The present invention relates to a method for preparing yohimbine by using supercritical extraction combined with steaming technology, comprising the following steps: 1) crushing the raw material, heating and steaming; 2) performing supercritical gradient extraction, extracting twice in total, and collecting the second supercritical extraction paste; 3) adding a mixed solvent to the second supercritical extraction paste, stirring, filtering and collecting the precipitate; 4) using an organic solvent to heat dissolve the precipitate, adding an adsorbent for adsorption, filtering and collecting the filtrate, concentrating the filtrate and standing it until the crystals are completely precipitated, filtering and collecting the crystals again, rinsing and drying the crystals in sequence, and obtaining yohimbine.

This invention provides a strain of Akkermansia myxophilus ( Akkermansia muciniphila The present invention provides a probiotic preparation comprising the aforementioned Akkermansia myxophilus or its post-genetically modified organism (PGA). The Akkermansia myxophilus or its post-genetically modified organism (PGA) of the present invention can improve vascular endothelial cell function, increase testosterone secretion, and thus improve erectile dysfunction and reproductive capacity. The probiotic preparation of the present invention may comprise the aforementioned Akkermansia myxophilus or its post-genetically modified organism (PGA) and yohimbine. This preparation can improve erectile dysfunction caused by vascular endothelial dysfunction, improve reproductive function in aged mice, and the components in this preparation have a synergistic effect.